How best to use new therapies in multiple myeloma

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Advances in the molecular understanding of myeloma have led to the development of novel agents such as immunomodulatory drugs (IMiDs) and proteasome inhibitors (bortezomib). When used alone, these agents have significant activity against myeloma and responses increase significantly when they are combined with additional agents including glucocorticosteroids and chemotherapeutic agents such as alkylators. There is a drive to use these novel agents in patients with newly diagnosed myeloma, where they lead to impressive response rates with increasing duration of responses. In addition, novel agents are now the mainstays of therapy for relapsed disease. In the following paper, we summarize the key observations from recent completed and ongoing studies that determined the effect of these novel therapies both in the setting of newly diagnosed myeloma and for relapsed disease. We also discuss our approach to the use of these agents in specific myeloma settings.

Original languageEnglish (US)
Pages (from-to)91-100
Number of pages10
JournalBlood Reviews
Issue number3
StatePublished - May 2010


  • Bortezomib
  • Immunomodulatory agents (IMiDs)
  • Lenalidomide
  • Proteasome inhibitors
  • Thalidomide

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'How best to use new therapies in multiple myeloma'. Together they form a unique fingerprint.

Cite this